|
🐜
|
To switch or not to switch: results of a nationwide guideline of mandatory switching from originator to biosimilar etanercept. One-year treatment outcomes in 2061 patients with inflammatory arthritis from the DANBIO registry
24 auth.
B. Glintborg,
A. Loft,
E. Omerovic,
O. Hendricks,
A. Linauskas,
J. Espesen,
K. Danebod,
D. Jensen,
H. Nordin,
E. B. Dalgaard,
...
S. Chrysidis,
S. Kristensen,
J. Raun,
H. Lindegaard,
N. Manilo,
S. H. Jakobsen,
I. Hansen,
Dorte Dalsgaard Pedersen,
I. Sørensen,
L. Andersen,
J. Grydehøj,
F. Mehnert,
N. Krogh,
M. Hetland
|
7 |
2018 |
7
🐜
|
|
🐜
|
Thymus size at 6 months of age and subsequent child mortality.
10 auth.
M. Garly,
S. Trautner,
C. Marx,
K. Danebod,
J. Nielsen,
H. Ravn,
...
C. Martins,
C. Balé,
P. Aaby,
I. Lisse
|
5 |
2008 |
5
🐜
|
|
🐜
|
Self-protection strategies and health behaviour in patients with inflammatory rheumatic diseases during the COVID-19 pandemic: results and predictors in more than 12 000 patients with inflammatory rheumatic diseases followed in the Danish DANBIO registry
21 auth.
B. Glintborg,
D. Jensen,
Sara Engel,
L. Terslev,
M. Pfeiffer Jensen,
O. Hendricks,
M. Østergaard,
Simon Horskjær Rasmussen,
T. Adelsten,
A. Colic,
...
K. Danebod,
M. Kildemand,
A. Loft,
H. Munk,
J. K. Pedersen,
R. Østgård,
Christian Møller Sørensen,
N. Krogh,
J. Agerbo,
C. Ziegler,
M. Hetland
|
5 |
2021 |
5
🐜
|
|
🐜
|
2017 ACR/ARHP Annual Meeting Abstract Supplement.
22 auth.
B. Glintborg,
E. Omerovic,
K. Danebod,
J. Vendelbo,
H. Nordin,
A. Loft,
S. Chrysidis,
J. Raun,
O. Hendricks,
H. Lindegaard,
...
J. Espesen,
S. H. Jakobsen,
I. Hansen,
J. Grydehøj,
E. B. Dalgaard,
Dorte Dalsgaard Pedersen,
N. Manilo,
L. Andersen,
S. Kristensen,
A. Linauskas,
N. Krogh,
M. Hetland
|
5 |
2017 |
5
🐜
|
|
🐜
|
Comparative effectiveness of two adalimumab biosimilars in 1318 real-world patients with inflammatory rheumatic disease mandated to switch from originator adalimumab: nationwide observational study emulating a randomised clinical trial
21 auth.
H. Nabi,
S. Georgiadis,
A. Loft,
O. Hendricks,
D. Jensen,
M. Andersen,
S. Chrysidis,
A. Colic,
K. Danebod,
Mohamad Redha Hussein,
...
M. Kalisz,
S. Kristensen,
N. Lomborg,
N. Manilo,
H. Munk,
J. K. Pedersen,
J. Raun,
F. Mehnert,
N. Krogh,
M. Hetland,
B. Glintborg
|
4 |
2021 |
4
🐜
|
|
🐜
|
FRI0190 Clinical outcomes from a nationwide non-medical switch from originator to biosimilar etanercept in patients with inflammatory arthritis after 5 months follow-up. results from the danbio registry
24 auth.
B. Glintborg,
Inge Juul Sørensen,
A. G. Loft,
J. Espesen,
D. Jensen,
K. Danebod,
S. Dieperink,
Oliver Hendricks,
I. J. Hansen,
A. Linauskas,
...
S. Kristensen,
L. Andersen,
Mohammad Hossein,
H. Nordin,
B. Andersen,
S. Chrysidis,
J. Raun,
H. Lindegaard,
N. Manilo,
J. Grydehøj,
E. B. Dalgaard,
Dorte Dalsgaard Pedersen,
Krogh Niels Steen,
M. Hetland
|
4 |
2017 |
4
🐜
|
|
🐜
|
POS1170 SELF-PROTECTION STRATEGIES, HEALTH BEHAVIOR AND DISEASE ACTIVITY DURING THE FIRST WAVE, RE-OPENING AND SECOND WAVE OF THE COVID-19 PANDEMIC IN >7000 DANISH PATIENTS WITH INFLAMMATORY ARTHRITIS
20 auth.
B. Glintborg,
D. Jensen,
Sara Engel,
L. Terslev,
M. P. Jensen,
O. Hendricks,
M. Østergaard,
S. H. Rasmussen,
T. Adelsten,
K. Danebod,
...
A. Colic,
M. Kildemand,
A. Loft,
H. Munk,
J. Pedersen,
R. Østgård,
C. M. Sørensen,
N. Krogh,
C. Ziegler,
M. Hetland
|
3 |
2021 |
3
🐜
|
|
🐜
|
Impact of the COVID-19 pandemic on treat-to-target strategies and physical consultations in >7000 patients with inflammatory arthritis
21 auth.
B. Glintborg,
D. Jensen,
L. Terslev,
M. P. Jensen,
O. Hendricks,
M. Østergaard,
Sara Engel,
Simon Rasmussen,
T. Adelsten,
A. Colic,
...
K. Danebod,
M. Kildemand,
A. Loft,
H. Munk,
J. K. Pedersen,
R. Østgård,
C. M. Sørensen,
N. Krogh,
J. Agerbo,
C. Ziegler,
M. Hetland
|
3 |
2021 |
3
🐜
|
